Caliber Imaging & Diagnostics (LCDX) Stock Price, News & Analysis
Company Description
Caliber Imaging & Diagnostics (OTC Link: LCDX) is classified in the medical devices industry within the Healthcare sector and carries a market capitalization of $3.7M.
LCDX has gained 500.0% over the past year. Shares last traded at $0.0006.
This page collects what Stock Titan holds for LCDX, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Caliber Imaging & Diagnostics (LCDX) stock last closed at $0.0006. Over the past 12 months, the stock has gained 500.0%. At a market capitalization of $3.7M, LCDX is classified as a micro-cap stock with approximately 8.5M shares outstanding.
Latest News
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Caliber Imaging & Diagnostics (LCDX) currently stands at 3.0 thousand shares, representing 0.0% of the float. This relatively low short interest suggests limited bearish sentiment. With 17.1 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Caliber Imaging & Diagnostics (LCDX) currently stands at 17.1 days, up 38.3% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 56% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 19.9 days.
LCDX Company Profile & Sector Positioning
Caliber Imaging & Diagnostics (LCDX) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing LCDX often look at related companies in the same sector, including Odyssey Health Inc (ODYY), Qscreen AI Inc (PMEDF), Kelyniam Global Inc (KLYG), Lattice Biologic (LBLTF), and Bioelectronics Corp (BIEL). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate LCDX's relative position within its industry.